Telum Therapeutics
The worrying and increasing development of bacterial resistance has led to the search of alternative substances to antibiotics.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
€1.0m | Seed | ||
| Total Funding | 000k | ||
| EUR | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | (98 %) | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (959 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (676 %) | (55807 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Telum Therapeutics SL is a pioneering biotechnology company that focuses on developing innovative treatments to combat bacterial infections, particularly those resistant to traditional antibiotics. The company specializes in the use of phage-encoded lytic proteins, also known as enzybiotics, which are proteins derived from bacteriophages (viruses that infect bacteria) that can break down bacterial cell walls. This approach offers a promising alternative to conventional antibiotics, especially in the face of rising antibiotic resistance.
Telum Therapeutics serves a global market, targeting healthcare providers, hospitals, and pharmaceutical companies that are in need of new solutions to treat multidrug-resistant bacterial infections. The company operates primarily in the drug discovery and biotechnology sectors, focusing on serious infections caused by Gram-negative bacteria such as Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa, as well as Gram-positive bacteria like Staphylococcus aureus and vancomycin-resistant Enterococci.
The business model of Telum Therapeutics revolves around the research and development (R&D) of these enzybiotics. The company progresses its discoveries from the initial research phase through preclinical trials, and eventually aims to bring these treatments to market. Revenue is generated through a combination of research grants, partnerships with larger pharmaceutical companies, and eventually, the commercialization of their proprietary treatments.
Telum Therapeutics is currently advancing several products in its development pipeline, each targeting different types of resistant bacterial infections. These products are in various stages of discovery and preclinical development, with patents filed to protect their innovative solutions.
In summary, Telum Therapeutics is at the forefront of addressing the critical issue of antibiotic resistance through its cutting-edge enzybiotic technology, aiming to bring new, effective treatments to the global healthcare market.
Keywords: enzybiotics, biotechnology, drug discovery, antibiotic resistance, bacteriophages, Gram-negative bacteria, Gram-positive bacteria, healthcare, R&D, pharmaceutical partnerships.